The data showed that CD24 expression was significantly upregulated in most cancers, including breast carcinoma (BRCA), cholangiocarcinoma (CHOL), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous carcinoma (LUSC), uterine corpus endometrial carcinoma (UCEC), pheochromocytoma and paraganglioma (PCPG), stomach adenocarcinoma (STAD), bladder urothelial carcinoma (BLCA), and cervical squamous carcinoma (CESC) (Figure 2A). Here, CD24 is linked to bladder transitional cell carcinoma.